Cagrilintide, an investigational novel long-acting acylated amylin analogue, functions as an agonist for nonselective amylin receptors (AMYR) and the calcitonin G protein-coupled receptor (CTR). It significantly reduces food intake and induces weight loss, showing promise for obesity research [1] [2] [3].